GlassScriptPhysician profile
Hinalben Patel
NPI 1801528658
$4,108.57
in general payments reported to CMS, 2019-2025
28 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,311 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,108.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $604.64 | 2024-2025 | |
| Pfizer INC. | $351.03 | 2024-2025 | |
| Sk Life Science, INC. | $346.52 | 2024-2025 | |
| Argenx US, INC. | $338.79 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $308.05 | 2024-2025 | Nayzilam, Briviact, Rystiggo |
| Biogen, INC. | $273.90 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Alexion Pharmaceuticals, INC. | $231.96 | 2024-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $201.89 | 2024-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $169.36 | 2024-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Genentech USA, INC. | $145.81 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Neurelis, INC. | $145.03 | 2024-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $140.56 | 2024-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $138.47 | 2024-2025 | |
| Abbvie INC. | $110.66 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $105.63 | 2024-2025 | Nuplazid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $97.59 | 2025 | Zeposia |
| Merz Pharmaceuticals, LLC | $75.97 | 2025 | Xeomin |
| Lilly USA, LLC | $70.10 | 2024 | Emgality, Amyvid |
| Teva Pharmaceuticals USA, INC. | $39.92 | 2024 | Ajovy |
| Scilex Pharmaceuticals INC. | $36.01 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $35.13 | 2024 | |
| Boston Scientific Corporation | $25.83 | 2025 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $23.88 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $20.91 | 2024 | Ponvory |
| Amgen INC. | $19.66 | 2025 | Uplizna |
| Janssen Biotech, INC. | $18.74 | 2025 | |
| Immedica Pharma US, INC. | $17.85 | 2024 | |
| Acorda Therapeutics, INC | $14.68 | 2024 | Inbrija, Ampyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hinalben Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.